Robin is a CFO with deep experience across life sciences, technology, and manufacturing, partnering with ambitious businesses to scale, raise capital, and deliver successful exits. A Fellow of the ICAEW with a Corporate Finance qualification, he has led fundraising from seed to IPO, guided trade sales and PE acquisitions, and built finance functions that drive growth and transformation. Known for his hands-on approach and investor network, Robin brings both financial rigour and operational insight to help companies achieve their next stage of development.

His record includes shaping exit strategies that have delivered landmark deals, such as the £230m sale of Bio Products Laboratory to Bain Capital, the £75m trade sale of CP Electronics to Legrand, and securing multi-million-pound equity, debt, and grant funding for innovative MedTech and biotech ventures.

Beginning his career with KPMG before moving into private equity at Legal & General Ventures, Robin brings the perspective of both investor and operator. He is known for his ability to stabilise, scale, and prepare businesses for growth and exit, with a steady hand in high-pressure environments.

Robin thrives at the intersection of science and finance, most recently serving as COO/CFO for IsomAb, a university spin-out developing a monoclonal antibody therapy. Earlier, he played a pivotal role in the commercialisation of groundbreaking diagnostics at Imspex and the launch of novel therapeutics at Purespring. His expertise extends beyond financing into operational execution: implementing ERP and FP&A systems, reshaping finance functions, and aligning multi-departmental strategies with investor expectations.